# An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

> **NCT02431260** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 69 (actual)

## Conditions studied

- Solid Tumors and Hematologic Malignancy

## Interventions

- **DRUG:** INCB054329 Monotherapy

## Key facts

- **NCT ID:** NCT02431260
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-14
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.
- **Last updated:** 2019-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431260, "An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02431260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*